What is Progentec Diagnostics?
Progentec Diagnostics, Inc. operates at the intersection of advanced proteomics and digital health, specifically targeting systemic lupus erythematosus and multiple sclerosis. The company's flagship aiSLE DX Family of Tests represents a significant advancement in the field, providing clinicians with the ability to predict disease flares and monitor activity with unprecedented precision. Beyond diagnostic hardware, the company maintains the LupusCorner platform, which serves as a digital ecosystem for patient empowerment, health management, and community engagement. By bridging the gap between clinical diagnostics and remote patient monitoring, Progentec is effectively positioning itself as a leader in the proactive care segment of the autoimmune market.
How much funding has Progentec Diagnostics raised?
Progentec Diagnostics has raised a total of $5.2M across 2 funding rounds:
Series A
$5M
Debt
$172K
Series A (2020): $5M with participation from Mayo Clinic, Stanford University, Burns & Stowers Investments LLC, OCA Ventures, NMC Health, Plains Venture Partners, Oklahoma Seed Capital Fund, Oklahoma Angel Capital Fund II, and Oklahoma Medical Research Foundation
Debt (2021): $172K led by PPP
Key Investors in Progentec Diagnostics
Mayo Clinic
A nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research with a focus on complex health conditions.
Stanford University
A world-leading research university known for its entrepreneurial character and interdisciplinary approach to solving complex engineering and scientific problems.
OCA Ventures
A venture capital firm dedicated to assisting entrepreneurs in the development of successful companies by providing resources to foster innovation and market growth.
What's next for Progentec Diagnostics?
With the recent influx of capital, Progentec Diagnostics is well-positioned to deepen its research and development efforts, particularly in expanding the clinical utility of its biomarker-driven diagnostic suite. The strategic focus will likely shift toward scaling the commercial reach of the aiSLE DX platform and enhancing the digital infrastructure of the LupusCorner ecosystem. As the company matures, the integration of artificial intelligence into its diagnostic workflows will remain a primary driver of competitive advantage, allowing for more personalized treatment pathways. Investors are closely watching how the firm leverages these resources to navigate the complex regulatory environment of medical diagnostics while simultaneously expanding its footprint in international healthcare markets.
See full Progentec Diagnostics company page
